BioAtla (NASDAQ:BCAB) Announces Quarterly Earnings Results, Beats Expectations By $5.78 EPS

BioAtla (NASDAQ:BCAB) released its quarterly earnings data on Friday. The company reported ($4.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.00) by $5.78, FiscalAI reports.

BioAtla Stock Down 2.3%

NASDAQ:BCAB opened at $4.27 on Friday. The stock’s fifty day moving average is $6.17 and its two-hundred day moving average is $19.64. BioAtla has a 52 week low of $3.92 and a 52 week high of $71.50. The stock has a market capitalization of $7.09 million, a price-to-earnings ratio of -0.08 and a beta of 0.81.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BCAB. Acadian Asset Management LLC lifted its stake in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Marshall Wace LLP acquired a new position in BioAtla during the fourth quarter worth $508,000. Millennium Management LLC grew its holdings in shares of BioAtla by 123.4% in the fourth quarter. Millennium Management LLC now owns 762,394 shares of the company’s stock valued at $433,000 after purchasing an additional 421,072 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of BioAtla in the fourth quarter valued at approximately $104,000. Finally, Susquehanna International Group LLP grew its holdings in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of BioAtla to a “hold” rating in a research report on Saturday, April 11th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $200.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.